Press releases

November 26, 2024

Ultragenyx to Participate in Investor Conferences in December

Read more

November 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 09, 2024

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

Read more

November 05, 2024

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Read more

October 29, 2024

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

Read more

October 18, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

October 07, 2024

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

Read more

October 03, 2024

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Read more

September 26, 2024

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

Read more

September 18, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more